“I want my book to capture the reader’s attention, and help them become aware of various ways they can help their children,” said Lelewer. “We still have a major problem in this country with children and adults having reading issues and other learning struggles.”
Initially published in 1994, “Something’s Not Right” won a Parents Choice Award. Lelewer has gone through and updated the book to still address dyslexia, but also ADD, ADHD, and those on the upper end of the autism spectrum. She also completely revised the reference guide as a helpful resource for parents, teachers and children.
“If you have a child with dyslexia and/or other types of learning disabilities, this book is the first step in a long but very rewarding road,” said Lelewer. “It’s not easy, but with early diagnosis, appropriate education, warmth, understanding, and nurturing, the future can be bright for an individual with these learning problems.
Something’s Not Right 2nd Edition: One family’s struggle with learning disabilities By Nancy Lelewer ISBN: 9781665734684 (softcover); 9781665734660 (hardcover); 9781665734677 (electronic) Available at Archway Publishing, Amazon and Barnes & Noble
About the author Nancy Lelewer received a BA from Sarah Lawrence College, Bronxville, NY, an Associate in Neurology from Harvard Medical School, Cambridge, Mass., and was a research affiliate at MIT’s Man Vehicle lab: Center for Space Research, Cambridge, Mass. Her work was published in Cortex and Annals of Dyslexia. She was a cofounder of Permobil, a Swedish wheelchair company, today the largest computerized wheelchair company in the world. Lelewer has served on three dyslexia boards and spent five years as chairwoman of the board for a school for dyslexic boys. She has four children, eight grandchildren and six great-grandchildren, and currently resides in Boston, Mass. To learn more, please visit http://www.NancyLelewer.com.
IITs vs. Industry-Sponsored Trials: Same Challenges, Different Budgets
The cost of clinical trials can range from $100,000 to well over $30 million, with significant variations based on factors such as the trial type, development phase, and focus of treatment.(2) Dr. Rajasimha explains, “The end product of an IIT is a publication, whereas, in a pharmaceutical industry-sponsored clinical trial, the end result is a marketing approval for the drug or device by the Food and Drug Administration (FDA) or the regulator. That’s the main difference. But operationally, the challenges are still the same, which means the budgets have to be the same — but they’re not. IITs have significantly lower budgets compared to industry-sponsored trials because there are potential revenue-generating sales soon after industry-sponsored clinical trials, or at least after phase III. IITs don’t have that. There is no immediate revenue benefit for IITs — with the exception of drug repurposing trials.”
The Real-World Significance of IITs
IITs are particularly valuable for exploring questions that fall outside the scope of pharmaceutical industry interests, such as off-label uses, comparing treatments from different companies, and assessing cost-effectiveness. The concept of repurposing drugs has emerged as a particularly viable approach in the quest to create treatments for rare diseases. A recent study revealed that 75% of the initiatives to develop repurposed drugs for rare conditions, approved between 2016 and 2020, were initiated through IITs within academic institutions.(3)
IITs represent the majority of all clinical trials conducted.(4) Currently, there are a total of 91,519 active studies.(5) The National Center for Biotechnology Information (NCBI) analyzed interventional clinical trials worldwide, using data from ClinicalTrials.gov between January 01, 2015, and December 31, 2021. This allowed them to compare IITs with industry-sponsored studies based on funding type. Their analysis covered all four phases of drug development. Phase I trials were primarily industry-sponsored (over 70%). Phase II trials were evenly split between academia and industry, while Phase III trials were nearly equal (IIT: 47%, industry: 53%). Academia predominantly sponsored Phase IV trials (75%).(6)
An investigator’s role in an IIT mirrors that of other clinical trials. Their essential duties include ensuring compliance with regulations, safeguarding subjects’ rights and safety, and managing investigational product use. Specific responsibilities encompass adhering to the investigational plan, maintaining case histories, reporting progress and safety data, obtaining informed consent, overseeing drug usage, and facilitating Institutional Review Board (IRB) reviews and FDA inspections.(7)
Leveling the Playing Field With World-Class Software Solutions
IITs are beset by the prohibitive costs of clinical research, particularly broad-ranging monitoring processes that focus on irrelevant details.(4) Ongoing challenges to this invaluable research include financial constraints, regulatory hurdles, staff training, limited statistical expertise, and issues with data management and medical writing. A National Institutes of Health (NIH) study suggests establishing Clinical Trials or Research Units in decentralized academic centers that would have the necessary expertise in all aspects of the design and execution of the clinical trial. They could also involve investigators in other countries as clinical trial counterparts to engage in large-scale multicentric studies.(1) IITs can take advantage of decentralized tools such as remote video, e-consent, or capturing patient-reported outcomes data remotely through mobile-friendly apps and televisits.
IITs can benefit from the same world-class trial management software utilized by industry-sponsored trials but at affordable prices. That is why Dr. Rajasimha and his team recently launched their “protocol to publication” offering centered around the J eeva™ eClinical Cloud, a purpose-built, unified SaaS platform with all the features and functionality to enable IIT hybrid or decentralized clinical trials under one login from any browser-enabled mobile device. Jeeva’s team assists academic investigator-initiated trials with study design and protocol writing, offering expert guidance and support, seamless eClinical solutions, enhanced study configuration, data management, biostatistics, and manuscript preparation.
Dr. Rajasimha attests, “Jeeva is proud to offer an affordable and comprehensive solution for academic principal investigators, supporting them from the initial protocol preparation phase to publication. Our end-to-end turnkey solution ensures a smooth and efficient workflow for investigator-initiated trials, assisting academic researchers conducting both interventional and observational cohort studies.”
To learn more about Jeeva’s cost-effective solution for IITs, visit our website https://jeevatrials.com/.
About Jeeva Informatics Solutions The personal experience of losing a child born with a rare congenital disorder and a brother with a chronic disease became the springboard for Dr. Harsha Rajasimha to apply his years of postdoctoral research experience at the NIH and FDA to accelerate therapies for rare and common conditions. He founded Jeeva with the mission of lowering the cost of drug development and accelerating the speed of clinical trials by purpose-building a modern technology platform that empowers sponsors to run clinical trials, with fewer fragmented systems, fewer employees, with significantly less burden on clinical researchers and patients, which has allowed for a more globally diverse population to access clinical trials remotely.
Today the Jeeva eClinical Trial platform supports sponsors and CROs across the globe helping reduce the logistical burdens on patients and study teams by over 70%. Its complete suite of technology supports fully decentralized and hybrid clinical trials and has resulted in being selected by research hospitals, CROs, and sponsors developing pioneering therapeutics such as Frantz Viral Therapeutics and ImmunoACT. The Virginia-based company’s modular cloud-resident software-as-a-service is highly scalable and facilitates patient enrollment, engagement, and evidence generation in clinical trials from one login from any browser-enabled mobile device. Visit https://jeevatrials.com/
References 1. Konwar, Mahanjit, et al. “Investigator-Initiated Studies: Challenges and Solutions.” Perspectives in Clinical Research, U.S. National Library of Medicine, 2018, ncbi.nlm.nih.gov/pmc/articles/PMC6176691/. 2. V. “What Should Be Included in a Clinical Trial Budget for 2022.” Mosio, 10 June 2022, mosio.com/clinical-trial-budget/. 3. Aacute;lamo, Marta del, et al. “Identifying Obstacles Hindering the Conduct of Academic-Sponsored Trials for Drug Repurposing on Rare-Diseases: An Analysis of Six Use Cases – Trials.” BioMed Central, BioMed Central, 15 Sept. 2022, trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06713-y. 4. Buyse, Marc, et al. “Central Statistical Monitoring of Investigator-Led Clinical Trials in Oncology.” International Journal of Clinical Oncology, U.S. National Library of Medicine, July 2020, ncbi.nlm.nih.gov/pmc/articles/PMC7308734/. 5. CTG Labs – NCBI, clinicaltrials.gov/search?aggFilters=funderType%3Anih+fed+other%2Cstatus%3Anot+rec+act+enr. Accessed 7 Sept. 2023. 6. Hoffmann, Jean-Marc, et al. “Academic Clinical Trials: Publication of Study Results on an International Registry-We Can Do Better!” Frontiers in Medicine, U.S. National Library of Medicine, 24 Nov. 2022, ncbi.nlm.nih.gov/pmc/articles/PMC9729766/. 7. Meghan Hosely, Marketing Copywriter. “Beginner’s Guide to Investigator-Initiated Trials.” Advarra, 31 Oct. 2022, advarra.com/blog/beginners-guide-to-investigator-initiated-trials/.
Media Contact
Karla Jo Helms, JOTO PR™, 727-777-4619, [email protected], jotopr.com
“We are very excited to bring Kevin onboard,” said Young. “He is a visionary with a success rate to back up his bold plans, as evidenced by his remarkable track record in growing annual recurring revenue, client numbers, and client satisfaction.”
McDonald has held executive positions in operations, client management, product strategy and business development at leading healthcare companies including HMS, Cotiviti and Discovery Health Partners. Most recently he served as Chief Growth Officer for two venture capital backed startups bringing innovative solutions to healthcare payers.
McDonald received a BA and an MBA from Union College in Schenectady, NY, and has been a featured speaker at several healthcare conferences.
About MedReview
Headquartered in the financial district of New York City and serving all U.S. states and territories, MedReview has been a leading provider of payment integrity, utilization management, and quality surveillance services for more than 40 years. A physician-led organization with a passion for ensuring that health care claims fairly represent the care provided, MedReview provides timely independent hospital billing audits and DRG clinical validation reviews on behalf of health plans, government agencies, and Taft-Hartley organizations, saving millions of dollars for its clients each year. For more information, please visit http://www.medreview.us.
Sandra Kirkwood of TruBlue of Olmsted Falls & Avon, echoes this sentiment. “It’s not uncommon for seniors to be at home and do things they shouldn’t because they don’t have anyone to help,” she said. “If you break your hip, fall prevention becomes extremely crucial. We aim to be the cushion that prevents such catastrophic events from happening.”
As part of the ‘Grab the Bar’ initiative targeting fall prevention and senior bathroom safety, Close the Gap in Senior Care has allocated 100 free grab bar installations to TruBlue for September. “Since September is Fall Prevention Month, it felt like a natural pairing to partner with TruBlue since it would allow us to expand the reach of our mission to allow seniors to age safely in their own homes,” said Deborah Chaney of the nonprofit. Anyone can nominate a deserving senior in their community for this valuable service through the end of the month (or while supplies last) by visiting CloseTheGapInSeniorCare.org. All nominees will receive a free Senior Home Safety Assessment by a Certified Senior Home Safety Specialist — a $199 value. Seniors who are selected will have grab bars, installed in their homes by their local TruBlue franchise free of charge, helping to address other home modification needs.
“I was drawn to TruBlue’s mission of helping seniors, and this campaign allows us to do just that,” said Kear. “To date, we’ve probably helped around 20 to 30 people in San Antonio alone. That may seem like a small number, but for each individual and family, it’s life-changing. We encourage you to nominate seniors in your service area. This initiative is about more than just installing grab bars; it’s about creating a lasting impact and offering peace of mind.”
TruBlue is dedicated to providing a complete range of home care services, from routine maintenance to full-scale renovations. The Fall Prevention campaign underscores the brand’s commitment to create safer, more accessible homes, particularly for seniors who wish to age in place.
“Being part of TruBlue allows us to touch a lot more clientele,” said Kirkwood. “My mission and passion in life is to help as many people as I can stay in their home safe and sound. TruBlue allows us to do that. We have an opportunity every day to educate people, whether younger or older, about staying safe and maintaining the home they have worked hard for. It feels very fulfilling to be a part of TruBlue. At the end of the day, we have impacted many people’s lives in a very positive way.”
Overall, TruBlue understands the severe impact a fall can have on an individual and their family. It affects seniors not just physically but also mentally with their confidence and independence. “Our campaign promotes awareness and provides practical solutions, from home modifications by installing grab bars, to education about common risk factors in the home,” said Sean Fitzgerald, TruBlue’s President. “This campaign embodies our commitment to enrich the lives of those we serve, fostering a safe and secure living environment for every individual.”
TruBlue Home Service Ally® provides a unique and affordable approach to helping busy adults and seniors live a worry-free life by offering trustworthy handyman, home maintenance and senior modification services. Helping you maintain your home both inside and out, TruBlue’s services include handyman projects and to-do list chores, preventative home maintenance programs, seasonal work, and senior modification services, all handled by a professional, bonded and insured Tru-Pro® Technician. TruBlue franchise owners are required to complete the Senior Home Safety Specialist certification program through Age Safe America. As certified specialists, TruBlue franchisees are able to perform aging in place home safety assessments and can make recommended safety modifications as needed.
About Close the Gap
Close the Gap in Senior Care is a 501(c)(3) charitable nonprofit organization that works to provide education and assistance for individuals looking to age in place safely. Their vision is to bring communities together to identify and address gaps in senior care. Their current initiative, Grab the Bars, aims to prevent senior falls at home. Not surprisingly, 80% of senior falls happen in the bathroom, but many of these falls could have been prevented with education and simple safety devices — saving money, dignity and even lives of seniors across the country. Close the Gap is encouraging everyone to donate today to help keep more seniors safe or nominate a senior in need to receive grab bars through their website: https://closethegapinseniorcare.org/
In January 2022, the Lung Cancer Action Network (LungCAN) took action by forming a dedicated Steering Committee of passionate advocates led by Jill Morningstar, a strong advocate with Capitol Hill experience, along with her husband Al Fitzpayne, a lung cancer survivor. The committee developed a strategic plan to increase the LCRP budget, aiming to allocate funding based on the amount needed to support top-rated research proposals from the previous year.
A major obstacle faced by lung cancer advocacy organizations was the lack of a unified web-based platform for contacting members of Congress. To address this challenge, LungCAN, acting as a neutral entity, created a platform that allowed members to direct their constituents to the LungCAN “Call to Action” website without the risk of losing organizational support. Through this platform, the lung cancer advocacy community joined forces, speaking with one voice to advocate for increased lung cancer research funding. The efforts yielded remarkable results:
The LCRP received a 25 percent increase in funding, receiving a record-breaking $25 million, the highest amount the program has ever been awarded.
The LCRP was the only CDMRP cancer program to receive an increase in funding.
Strategic social media engagement garnered a remarkable 55,000 combined impressions and 33.3 percent engagement on Twitter.
Approximately 1,847 individuals participated in the effort, reaching more than 400 legislators.
Advocates sent over 5,541 letters to legislators requesting $60 million for the LCRP through the LungCAN platform, lungcan.org/act.
Additional emails from advocates through GO2 and LUNGevity platforms exceeded 4,000.
A House “Dear Colleague” letter received more than 50 co-signers, the highest number ever.
The campaign garnered support from 80 associations and organizations, growing beyond Congress.
“This historic success highlights the power of unity and collaboration among lung cancer advocacy organizations,” said Dusty Donaldson, representing Lung Cancer Action Network. “By joining forces and speaking with one voice, we were able to secure increased funding for lung cancer research, which is essential in advancing our fight against this devastating disease.”
This project was a component of the LungCAN Advocacy Media Training project, funded by Lung Ambition Alliance, comprising AstraZeneca, Guardant Health, International Association for the Study of Lung Cancer, and the Global Lung Cancer Coalition.
About the IASLC: The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.
About the WCLC: The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2023.iaslc.org.
The AEGEAN trial is a double-blind, placebo-controlled phase 3 study that evaluated the use of perioperative durvalumab in combination with neoadjuvant chemotherapy compared to neoadjuvant chemotherapy alone. The trial involved adults with treatment-naïve resectable NSCLC (stage II-IIIB[N2]; AJCC 8th ed) and ECOG PS 0/1. Patients were randomized to receive either neoadjuvant durvalumab 1500 mg or placebo intravenously (IV) alongside platinum-based CT prior to surgery. Following surgery, patients received durvalumab 1500 mg or placebo IV, respectively. The primary endpoints of the trial were pathological complete response and event-free survival.
The study randomized 802 patients with treatment- naïve resectable NSCLC (stage II-IIIB[N2] and ECOG PS 0/1). Efficacy analyses were performed in the modified intent-to-treat population which comprised 740 patients with no documented EGFR mutations/ALK gene rearrangements (366 in the durvalumab arm and 374 in the placebo arm).
Lobectomy, sleeve resection, or bilobectomy were allowed as planned surgery (at enrolment); the protocol was amended with enrollment ongoing to exclude patients with tumors classified as T4 for any reason other than size (>7 cm) or whose planned surgery was pneumonectomy (originally allowed).
In the modified intent-to-treat population, 80.6% and 80.7% underwent surgery, respectively; 77.6% and 76.7% completed surgery, with disease progression the most common reason for canceled (6.8% vs 7.8%) or non-completed (1.4% vs 2.1% ) surgery. Among treated patients who underwent surgery, 17.3% and 22.2% had delayed surgery, most commonly for logistical reasons (e.g., scheduling issues; 9.5% vs. 12.3%). The median time from the last neoadjuvant treatment dose to surgery was the same in each arm (34.0 days). Among patients who underwent surgery, similar proportions in the durvalumab and placebo arms had open (49.2% vs 50.7%) and minimally invasive procedures (49.2% vs 47.0%); lobectomy (including sleeve resection and bilobectomy) was the most common procedure (88.1% vs 85.4%), followed by pneumonectomy (9.2% vs 9.6%). Among patients who completed surgery, a numerically higher proportion had R0 resection in the durvalumab versus placebo arm (94.7% vs 91.3%).
According to Dr. Mitsudomi, it is encouraging to see these comprehensive outcomes described in a robust phase 3 trial which showed that adding perioperative durvalumab to neoadjuvant CT did not adversely impact the feasibility, type, extent, or timing of surgery in patients with R-NSCLC and was associated with a tolerable surgical safety profile. Further, the addition of durvalumab resulted in numerically higher R0 resection rates.
AEGEAN data from outcomes for patients with documented EGFR mutations are also being presented at IASLC 2023 World Conference on Lung Cancer.
The AEGEAN study was conducted by AstraZeneca (LSE/STO/Nasdaq: AZN).
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.
About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2023.iaslc.org
Ibezapolstat is currently enrolling in a Phase 2b trial for C. difficile infection in U.S. centers across the country and nearing its goal to reach a targeted 36 patients at which point an Interim Analysis of the unblinded primary clinical endpoint and safety data will be reviewed by an…
“As the healthcare industry rapidly evolves, we have to not just evolve but stay ahead of the curve. Sympti represents our value to the public and our desire to help people with great accuracy when they are sick.” Alex Guastella, Co-Founder of Sympti.
Sympti has evolved into a comprehensive platform that will continue to transform how urgent care facilities operate by providing a patient scheduling and appointment reminder platform, as well as integrated data solutions. As the company continues to evolve, we have chosen Sympti as our new name to help us build on the success we’ve already achieved in the urgent care sector and to provide the flexibility to expand into other areas of health care.
“With this name change, our goal of finding immediate, zero-wait urgent care remains intact, while it gives us a chance to promote the brand more effectively, and allows us to focus on bigger and broader challenges in healthcare” said, Raghu Dhulipala, Co-Founder of Sympti.
Sympti is committed to helping healthcare providers to better serve patients by providing them with an innovative scheduling solution that streamlines appointment processes so they can spend more time delivering high-quality care. We extend our gratitude to our client base, partners, and employees for their continuous support and trust in Quick’rCare. We look forward to continuing to serve you under our name, Sympti.
For more information about the name change or to learn more about Sympti, please visit: http://www.sympti.com.
One of the first impressions a hospital makes on their patients and visitors is the quality of their food. After lengthy discussions and research, it was easy to see that the values of Culinary Services Group aligned with those of T.J. Regional Health.
“I trust Culinary Services Group as a partner because they are big enough to support us and deliver on their promises, yet small enough to care.” – Jim Lee, Executive Vice President for Support Services at T.J. Regional Health
Culinary Services Group aims to drive patient satisfaction through fresh, new menus that align with current food trends. The company will use technology to improve the overall dining experience. For patients, bedside orders will soon be placed using tablets. The company will install a state-of-the-art Point-of-Sale System at the hospital’s cafeteria-style retail space and its two bistro-style cafes. The new system will not only track revenues accurately, but it will provide consumer insights allowing the company to tailor its menus and offerings to the surrounding community. The enhanced dining program also offers T.J. Regional the opportunity to give back to the local community by partnering with Culinary Services Group on community outreach opportunities.
“Community Outreach is one of the pillars of this organization, and the partnership with CSG will allow us to do even more outreach in the communities we serve,” Lee said.
Culinary Services Group first entered the Kentucky market in 2021 and is invested in growing its regional footprint. The food service company exclusively serves hospitals, senior living, and behavioral health facilities through a unique approach. Each location they serve receives a customized menu, tailored to the preferences of its patients and staff while accounting for regional preferences and cooking styles. The company is also at the forefront of new technologies and innovative methods of food service through touchscreen devices, state-of-the-art software, and even robotics. To learn more about partnering with Culinary Services Group in Kentucky, please contact their sales team.
Rod Mollere, D.D.S., P.A. of El Paso, Texas, is now El Paso Family Dental and is serving patients of all ages and backgrounds. The successful and well-known dental practice has undergone several exciting changes, including an acquisition, a new website, and welcoming a new dentist.
EL PASO, Texas, Sept. 12, 2023 /PRNewswire-PRWeb/ — Rod Mollere, D.D.S., P.A. of El Paso, Texas, has rebranded as El Paso Family Dental and is serving patients of all ages and backgrounds. The successful and well-known dental practice has undergone several exciting changes, including introducing a new website (https://www.elpasofamilydentalcare.com) and welcoming a new dentist.
El Paso Family Dental is proud to announce general dentist Dr. Alessandro Retis as the new lead dentist in the practice. Prior to moving to Texas, Dr. Retis completed a one-year oral & maxillofacial surgery residency at the LAC+USC Medical Center, Level 1 trauma center for downtown Los Angeles. During his residency, he was responsible for taking primary call for maxillofacial trauma and for teaching USC dental students dentoalveolar surgery and wisdom teeth extractions. His experience here will benefit all patients at El Paso Family Dental.
Dr. Retis is a 2019 UNLV School of Dental Medicine graduate and worked as a general dentist in Kingsville, Texas, prior to joining the practice. He and the El Paso Family Dental team are highly qualified and experienced in all areas of family dentistry. They welcome patients of all ages, providing individualized care that Texas and New Mexico dental patients expect and deserve.
In addition to welcoming Dr. Retis, El Paso Family Dental now has a new website at https://www.elpasofamilydentalcare.com. Their dental providers offer the following services to families from Northwest El Paso, Northeast El Paso, Logan Heights, Sunland Park, Prado Verde, Santa Teresa, Fort Bliss, East El Paso, Mission Valley, El Paso County, and all surrounding areas, including Chaparral, Mesquite Hills and Las Cruces, New Mexico:
Pediatric Dentistry (first dental visits, infants through adolescence)
Cosmetic Dentistry (including teeth whitening, restorative dentistry, crowns, and bridges)
Periodontal Care
“I am excited to provide quality dental care to individuals and families throughout the El Paso area. My team and I look forward to building relationships with those who entrust their care to us and helping them meet their dental health and cosmetic goals. Whether it’s a routine exam and cleaning, teeth whitening, or a dental emergency, you can count on us to be there for you,” says Dr. Alessandro Retis.
At El Paso Family Dental, patients are like family. Their staff greets every dental patient with a warm smile and a welcoming atmosphere at each visit. Dr. Retis and his team of dental professionals help patients of all ages feel relaxed and comfortable during their visit, no matter what they are there for.
Equipped with the latest technology, El Paso Family Dental provides advanced care to improve your dental health and enhance your overall experience.
About El Paso Family Dental
El Paso Family Dental is a general dentistry family practice located at 965 N Resler Dr, Suite 105, El Paso, TX 79912. They are available by phone at 915-585-2020 or online at https://www.elpasofamilydentalcare.com. Their office accepts many different types of dental insurance, including Texas and New Mexico Medicaid.
